Jesus San Miguel

Jesus San Miguel is one of the foundational figures in multiple myeloma research whose decades of work established the clinical and molecular framework for risk-adapted myeloma treatment. He led early trials of thalidomide and bortezomib in smoldering myeloma and active disease, and contributed to identifying high-risk cytogenetic markers and molecular stratification criteria. He is a principal investigator of the PETHEMA/GEM group's landmark myeloma studies and has contributed to developing MRD as a surrogate endpoint. He received the Paul Calabresi Award from ASCO for his contributions.